Ok folks. Let’s play a little “One of these things is not like the other; one of these things just doesn’t belong…” Sing along with me if you’d like. Or not. Either way, I’m betting the farm that you’re going to pick (drum roll please) Floppy Hats as your answer.
Raptiva, Reglan, Hydroxycut and Heparin are all drugs (one’s a supplement) that have either been directly linked to adverse (and dangerous) side effects and have been yanked or recalled from shelves by the FDA—or have received a more stringent black box warning in recent months. Each is a current legal issue with lawsuits pending.
Floppy Hats? That would be a suit, too, brought forth by Alfred G. Rava—a California lawyer. Seems he felt pretty injured (my words) when he didn’t receive a floppy hat as a giveaway at an Oakland A’s game in 2004. See, according to a great post by Rick Reilly over at ESPN.com (6/12/09), Read the rest of this entry »
The complete recall of Genentech’s psoriasis drug Raptiva throughout the US and some countries of the European Union will be finalized this week, after sales were suspended in April of this year due to the risk of serious Raptiva side effects, including a fatal brain infection known as progressive multifocal leukoencephalopathy (PML).
Although the overall risk of PML for patients on Raptiva is low, it appears to be increased in long-term users of the drug and in those with compromised immune systems. But the FDA announced that Raptiva would no longer be available in the United States by June 8, 2009. So that means a patient could get a prescription in June and potentially take Raptiva for at least 4 months or so after sales were initially suspended.
I don’t get it: if the amount of time a patient is on Raptiva is a crucial factor in developing PML, why was this drug phased out slowly instead of being wiped off the market in one fell swoop?
On Raptiva? Then the clock’s ticking. Your pharmacy will only give you a refill on your prescription till until Monday, June 8th. While we’re happy that Genentech decided to voluntarily withdraw Raptiva from the market given the drug’s link to the deadly progressive multifocal leukoencephalopathy (PML) infection, there’s one thing Genentech couldn’t take away: patients’ stress.
Think about it-you’re on Raptiva for psoriasis and you’ve been told that stopping Raptiva at once could either worsen your psoriasis or, worse yet, necessitate hospitalization. That’ll give you pause if you’re considering going cold turkey. But then again, you did receive that letter in the mail from Genentech advising you that you’ll need to stop taking it. Feeling caught between a rock and a hard place? You should be.
But before you stress yourself out even more, see your doctor first. You and your doctor need to come up with a plan to switch to another psoriasis treatment before coming off Raptiva. Beyond that (as if that isn’t enough), if you any questions about what recourse you may have as a result of being on Raptiva and being told you need to come off it pronto, you may want to ask a lawyer about your situation.
When it comes to a drug like Raptiva, the risks most certainly outweigh the benefits. On its extensive list of side effects—including a brain damage disease called progressive multifocal leukoencephalopathy (PML) that is lethal—the drug company should add STRESS. I’ve talked with several people and one nurse in particular, who took this psoriasis drug for a few years before noticing any side effects. None of the psoriasis sufferers I spoke with have been diagnosed with PML, but not a day goes by that they aren’t fearful. And because the disease is rare, not much is known about it. Gloria, the nurse I spoke with, said that much of the medical community hasn’t put 2 and 2 together. In Gloria’s case she was hospitalized for neurological problems. ” The doctors couldn’t say that Raptiva was the direct cause, but they didn’t rule it out either,” she said.